FIBROBIOLOGICS INC (FBLG)

US31573L1052 - Common Stock

1.985  -0.01 (-0.75%)

After market: 1.99 +0 (+0.25%)

Fundamental Rating

1

Taking everything into account, FBLG scores 1 out of 10 in our fundamental rating. FBLG was compared to 564 industry peers in the Biotechnology industry. FBLG has a bad profitability rating. Also its financial health evaluation is rather negative. FBLG does not seem to be growing, but still is valued expensively.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

FBLG had negative earnings in the past year.
FBLG had a negative operating cash flow in the past year.

1.2 Ratios

The Return On Assets of FBLG (-169.83%) is worse than 88.15% of its industry peers.
With a Return On Equity value of -649.58%, FBLG is not doing good in the industry: 82.05% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -169.83%
ROE -649.58%
ROIC N/A
ROA(3y)-201.8%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for FBLG so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

2

2. Health

2.1 Basic Checks

Compared to 1 year ago, FBLG has more shares outstanding
FBLG has a better debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -2.72, we must say that FBLG is in the distress zone and has some risk of bankruptcy.
FBLG has a Altman-Z score of -2.72. This is comparable to the rest of the industry: FBLG outperforms 48.47% of its industry peers.
FBLG has a Debt/Equity ratio of 0.04. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.04, FBLG is doing worse than 60.68% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Altman-Z -2.72
ROIC/WACCN/A
WACCN/A

2.3 Liquidity

A Current Ratio of 1.23 indicates that FBLG should not have too much problems paying its short term obligations.
FBLG has a Current ratio of 1.23. This is amonst the worse of the industry: FBLG underperforms 84.20% of its industry peers.
A Quick Ratio of 1.23 indicates that FBLG should not have too much problems paying its short term obligations.
The Quick ratio of FBLG (1.23) is worse than 82.94% of its industry peers.
Industry RankSector Rank
Current Ratio 1.23
Quick Ratio 1.23

More info and screens

0

3. Growth

3.1 Past

FBLG shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -321.92%.
EPS 1Y (TTM)-321.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.69%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 4.72% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y48.63%
EPS Next 2Y20.2%
EPS Next 3Y8.32%
EPS Next 5Y4.72%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

FBLG reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year FBLG is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.2%
EPS Next 3Y8.32%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for FBLG!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FIBROBIOLOGICS INC

NASDAQ:FBLG (1/2/2025, 8:00:02 PM)

After market: 1.99 +0 (+0.25%)

1.985

-0.01 (-0.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)N/A N/A
Inst Owners9.63%
Inst Owner Change25.55%
Ins Owners17.59%
Ins Owner Change-2.18%
Market Cap68.80M
Analysts82.22
Price Target13.01 (555.42%)
Short Float %9.43%
Short Ratio15.63
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)83.45%
Min EPS beat(2)78.21%
Max EPS beat(2)88.69%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-1.92%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)5.56%
EPS NY rev (3m)15%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 25.14
P/tB 25.14
EV/EBITDA N/A
EPS(TTM)-0.89
EYN/A
EPS(NY)-0.37
Fwd EYN/A
FCF(TTM)-0.3
FCFYN/A
OCF(TTM)-0.3
OCFYN/A
SpS0
BVpS0.08
TBVpS0.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -169.83%
ROE -649.58%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-201.8%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 61.7%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.23
Quick Ratio 1.23
Altman-Z -2.72
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-321.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.69%
EPS Next Y48.63%
EPS Next 2Y20.2%
EPS Next 3Y8.32%
EPS Next 5Y4.72%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-98.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-69.6%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-57.43%
OCF growth 3YN/A
OCF growth 5YN/A